Review of NICE Technology Appraisal Guidance no. no. 145; Cetuximab for the treatment of head and neck cancer

The Institute was proposing that the guidance should be transferred to the ‘static guidance list’ for Technology Appraisals.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

June 2011